PA
IMVT icon

Perceptive Advisors’s Immunovant IMVT Stock Holding History

Perceptive Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$5.28M – 115
2024
Q2 		$5.28M Buy
200,000
+100,000
+100% +$2.84M 0.13% 78
2024
Q1 		$3.23M Buy
+100,000
New +$3.65M 0.06% 100

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors's IMVT Position: Q2 2026 in Review

Perceptive Advisors reduced its Immunovant (IMVT) stake by 15% in Q2 2026, selling an estimated $7.31M and leaving 1,357,383 shares worth $52.3M. The position accounts for 0.79% of the portfolio, ranked #29.

Perceptive Advisors first reported a position in IMVT in Q2 2020 and has held it in 18 quarters since. The position peaked at $146M in Q3 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Perceptive Advisors held 1,357,383 shares of Immunovant worth $52.3M as of Q2 2026.
  • Perceptive Advisors sold 240,000 Immunovant shares in Q2 2026, an estimated $7.31M.
  • Immunovant made up 0.79% of Perceptive Advisors's portfolio in Q2 2026, its #29 holding.
  • Perceptive Advisors first reported a position in Immunovant in Q2 2020 and has held it in 18 quarters since.
  • Perceptive Advisors's Immunovant position peaked at $146M in Q3 2023.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.